Abstract
With the advances in molecular biology and biochemistry new imaging and treatment modalities based on the biological properties of tissues have been developed where important progress has been achieved using antibodies and peptides. This paper will concentrate on peptide vectors. When labeled with therapeutic radioisotopes these agents are suitable for endoradiotherapy and exploit the targeting potential for highly specific treatment which has been realized for antibodies against CD20 or peptides binding to somatostatin receptors. This novel class of pharmaceuticals offers the potential to develop specific therapies beyond the possibilities of current chemotherapy and radiation therapy. Furthermore, these achievements can be seen as proof of principle and encourage more research towards the identification of new specifically binding molecules. Activities towards the development of new biomolecules can be based on biotechnology methods. Rational design uses informations obtained from structure-activity relationship studies and conformational analyses of peptide structures. This approach relies on the identification of lead compounds and screening of various derivatives of these compounds. In contrast to rational design the central idea of black box approaches is to create vast libraries of possible variants of molecules and screen the population for the few compounds that show the property of interest. The attracting feature relies on the huge number of candidate molecules that can be used for further evaluation. After the characterization of the structure-function relationships for the lead compounds found in this process further improvement by rational design of analogs can be performed.
Keywords: Endoradiotherapy, peptides, phage display, ribosome display, targeted therapy
Current Medicinal Chemistry
Title: Endoradiotherapy with Peptides - Status and Future Development
Volume: 15 Issue: 3
Author(s): Uwe Haberkorn, Michael Eisenhut, Annette Altmann and Walter Mier
Affiliation:
Keywords: Endoradiotherapy, peptides, phage display, ribosome display, targeted therapy
Abstract: With the advances in molecular biology and biochemistry new imaging and treatment modalities based on the biological properties of tissues have been developed where important progress has been achieved using antibodies and peptides. This paper will concentrate on peptide vectors. When labeled with therapeutic radioisotopes these agents are suitable for endoradiotherapy and exploit the targeting potential for highly specific treatment which has been realized for antibodies against CD20 or peptides binding to somatostatin receptors. This novel class of pharmaceuticals offers the potential to develop specific therapies beyond the possibilities of current chemotherapy and radiation therapy. Furthermore, these achievements can be seen as proof of principle and encourage more research towards the identification of new specifically binding molecules. Activities towards the development of new biomolecules can be based on biotechnology methods. Rational design uses informations obtained from structure-activity relationship studies and conformational analyses of peptide structures. This approach relies on the identification of lead compounds and screening of various derivatives of these compounds. In contrast to rational design the central idea of black box approaches is to create vast libraries of possible variants of molecules and screen the population for the few compounds that show the property of interest. The attracting feature relies on the huge number of candidate molecules that can be used for further evaluation. After the characterization of the structure-function relationships for the lead compounds found in this process further improvement by rational design of analogs can be performed.
Export Options
About this article
Cite this article as:
Haberkorn Uwe, Eisenhut Michael, Altmann Annette and Mier Walter, Endoradiotherapy with Peptides - Status and Future Development, Current Medicinal Chemistry 2008; 15 (3) . https://dx.doi.org/10.2174/092986708783497256
DOI https://dx.doi.org/10.2174/092986708783497256 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Detection of Fungal Infections Using Radiolabeled Antifungal Agents
Current Drug Targets Epithelial-Mesenchymal Transitions and Cancer
Current Genomics Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Role of Gut Microbiota in Human Health and Diseases
Current Nutrition & Food Science Extracellular ATP and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Bioremediation of Toxic Heavy Metals: A Patent Review
Recent Patents on Biotechnology Review of Structures Containing Fullerene-C60 for Delivery of Antibacterial Agents. Multitasking model for Computational Assessment of Safety Profiles
Current Bioinformatics